Zoetis Inc.
NYSE:ZTSDrug Manufacturers - General
+$1.17 today
- Market cap
- $34.76B
- Beta
- 0.74
- P/E (TTM)
- 12.5
- EPS (TTM)
- $6.26
- Dividend yield
- 2.63%
Volume 4.66M
Average 6.20M
ZTS Other Financing Activities
Financing cash flows not reported separately.
Zoetis Inc.NYSE: ZTS
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities growth accelerates
Q2 FY2026 other financing activities of $6M (cash outflow) rose 100.0% year over year, ahead of the +88.9% change in trailing-twelve-month other financing activities. Sequentially, it fell 40.0% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.
Context
- Other financing activities amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +100.0% holds above the trailing-twelve-month pace of +88.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (14M) USD
- Year-over-year change
- -7.7%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14M) | -7.7% |
| FY2024 | 2024-12-31 | (13M) | -154.2% |
| FY2023 | 2023-12-31 | 24M | +149.0% |
| FY2022 | 2022-12-31 | (49M) | -8.9% |
| FY2021 | 2021-12-31 | (45M) | — |
Other Financing Activities vs competitors
How ZTS compares with its peers on the latest reported figures
- ZTS's LTM Jun 2026 other financing activities of $17M is the 4th largest of the 6 companies compared; the peer median is $11.06M.
- Its year-over-year change of +88.9% is the 2nd highest of 6, against a peer median of -25.3%.
- Other financing activities amounts to 0.2% of revenue for ZTS, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $631M | -3104.8% | — | 12.3% | |
| LTM Mar 2026 | $235.98M | +1924.5% | +24.8% | 15.7% | |
| LTM Jun 2026 | $227M | -25.3% | -18.3% | 0.3% | |
| LTM Jun 2026 | $17M | +88.9% | -34.1% | 0.2% | |
| LTM Sep 2026 | $11.06M | +64.4% | -24.8% | 0.2% | |
| LTM Aug 2026 | $1.98M | -67.0% | -62.7% | 0.2% | |
| Peer median (excluding ZTS) | $11.06M | -25.3% | -21.5% | 0.3% | |
Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.03B | 2.11B | 2.34B | 2.5B | 2.67B |
| Depreciation & Amortization | 448M | 465M | 491M | 497M | 487M |
| Deferred Income Tax | (80M) | (286M) | (61M) | (338M) | (52M) |
| Stock-Based Compensation | 58M | 62M | 60M | 74M | 83M |
| Change in Working Capital | (343M) | (699M) | (512M) | 79M | (408M) |
| Accounts Receivables | (155M) | (137M) | (102M) | (61M) | (236M) |
| Inventory | (366M) | (486M) | (361M) | (40M) | (199M) |
| Accounts Payables | (17M) | (29M) | 13M | 31M | 46M |
| Other Working Capital | 195M | (47M) | (62M) | 149M | (19M) |
| Other Non-Cash Items | 96M | 259M | 31M | 145M | 121M |
| Operating Cash Flow | 2.21B | 1.91B | 2.35B | 2.95B | 2.9B |
| Capital Expenditures | (477M) | (586M) | (732M) | (655M) | (621M) |
| Acquisitions (Net) | (14M) | (312M) | (59M) | 285M | (24M) |
| Purchases of Investments | (12M) | (9M) | (4M) | (5M) | (7M) |
| Sales of Investments | 44M | 23M | 12M | 62M | 0 |
| Other Investing Activities | 1M | 1M | 6M | (2M) | (96M) |
| Investing Cash Flow | (458M) | (883M) | (777M) | (315M) | (748M) |
| Debt Repayment | (604M) | 1.35B | (1.35B) | (3M) | 2.27B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (743M) | (1.59B) | (1.09B) | (1.86B) | (3.24B) |
| Dividends Paid | (474M) | (611M) | (692M) | (786M) | (889M) |
| Other Financing Activities | (45M) | (49M) | 24M | (13M) | (14M) |
| Financing Cash Flow | (1.86B) | (904M) | (3.11B) | (2.66B) | (1.87B) |
| Effect of Forex Changes | (12M) | (29M) | (7M) | (32M) | 39M |
| Net Change in Cash | (119M) | 96M | (1.54B) | (54M) | 325M |
| Free Cash Flow | 1.74B | 1.33B | 1.62B | 2.3B | 2.28B |
Zoetis Inc.
NYSE:ZTS
Intrinsic Alpha fair value
Locked
Current Price
$85.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.